- Primary research
- Open Access
Release and uptake of volatile organic compounds by human hepatocellular carcinoma cells (HepG2) in vitro
© Mochalski et al.; licensee BioMed Central Ltd. 2013
Received: 14 February 2013
Accepted: 13 July 2013
Published: 17 July 2013
Volatile organic compounds (VOCs) emitted by human body offer a unique insight into biochemical processes ongoing in healthy and diseased human organisms. Unfortunately, in many cases their origin and metabolic fate have not been yet elucidated in sufficient depth, thus limiting their clinical application. The primary goal of this work was to identify and quantify volatile organic compounds being released or metabolized by HepG2 hepatocellular carcinoma cells.
The hepatocellular carcinoma cells were incubated in specially designed head-space 1-L glass bottles sealed for 24 hours prior to measurements. Identification and quantification of volatiles released and consumed by cells under study were performed by gas chromatography with mass spectrometric detection (GC-MS) coupled with head-space needle trap device extraction (HS-NTD) as the pre-concentration technique. Most of the compounds were identified both by spectral library match as well as retention time comparison based on standards.
A total of nine compounds were found to be metabolised and further twelve released by the cells under study (Wilcoxon signed-rank test, p<0.05). The former group comprised 6 aldehydes (2-methyl 2-propenal, 2-methyl propanal, 2-ethylacrolein, 3-methyl butanal, n-hexanal and benzaldehyde), n-propyl propionate, n-butyl acetate, and isoprene. Amongst the released species there were five ketones (2-pentanone, 3-heptanone, 2-heptanone, 3-octanone, 2-nonanone), five volatile sulphur compounds (dimethyl sulfide, ethyl methyl sulfide, 3-methyl thiophene, 2-methyl-1-(methylthio)- propane and 2-methyl-5-(methylthio) furan), n-propyl acetate, and 2-heptene.
The emission and uptake of the aforementioned VOCs may reflect the activity of abundant liver enzymes and support the potential of VOC analysis for the assessment of enzymes function.
Volatile organic compounds (VOCs) emitted by the human body have a great potential for medical diagnosis and therapeutic monitoring [1–5]. Their analysis offers a unique insight into biochemical processes ongoing in healthy and diseased human organisms. Breath analysis holds a distinguished status in this context as it is non-invasive and breath biomarkers can provide valuable information on disease processes, or metabolic disorders occurring even in distant parts of the body. For instance, volatile compound profiles were shown to be different in lung cancer patients as compared to healthy controls [6–9] and proved to be useful in the quantification of oxidative stress [10, 11]. Unfortunately, the origin and metabolic fate of numerous breath VOCs have not been elucidated in sufficient depth, thereby limiting the clinical application of breath tests. In this context, the knowledge of precise biochemical pathways of volatile compound formation or at least the information if a compound is produced in human cells (both normal cells or cancerogenous cells), emitted by bacteria in the gut, or released by pathogenic organisms (e.g., bacteria, fungi) is highly desirable. For example, over the last few years an effort was made to pinpoint VOCs emitted specifically by cancer cells [12–16], bacteria [17–19], or fungi .
HepG2 liver cells are of particular interest in this context: volatile compounds released by the liver might be interesting biomarkers related to the activity of various enzymes including those involved in drug metabolism (such as cytochrome P450 enzymes). Here we investigate one of the most frequently studied liver cell lines, HepG2. This cell line has been derived from a 15 year old male patient with liver carcinoma. HepG2 cells possess epithelial morphology and secrete a variety of major plasma proteins (e.g., albumin, transferrin and the acute phase proteins fibrinogen, alpha 2-macroglobulin, alpha 1-antitrypsin, transferrin, and plasminogen). These cells can be grown successfully in large scale cultivation systems. Work by Castaneda et al.  established the production of undecane-2-one in HepG2 cells exposed to ethanol. However, a detailed GC-MS-based investigation of the release or uptake of volatile compounds by HepG2 cells is still lacking. Hence, the primary goal of this work was to identify volatile organic compounds released or metabolized by HepG2 hepatocellular carcinoma cells. For this purpose an experimental setup combining head-space needle trap extraction (NTD) and gas chromatography – mass spectrometry (GC-MS) was applied. GC-MS is the gold standard in the analysis of volatile compounds. The majority of compounds (with few exceptions) were identified not only by spectral library match, but also by comparison of retention times using native standards.
Results and discussion
Retention times, quantifier ions, LODs, RSDs, coefficients of variation and linear ranges of compounds under study
linear range [ppb]
Sulfide, ethyl methyl
Not quantified, RT confirmed
Total number of cells, number of living cells and viability at the end of the cultivation
Total number of cells ×106
Number of living cells ×106
Uptake of VOCs by HepG2 cells
Detection (n d ) and quantification (n q ) incidences, concentration ranges and medians in the headspace of medium and cell cultures
Sulfide, ethyl methyl
Although frequently the origin and metabolic fate of volatile organic compounds in human organism remain ambiguous, several biochemical pathways could explain the uptake and release of species by HepG2 cells. Aldehydes can be irreversibly oxidized by aldehyde dehydrogenases (ALDHs) to their corresponding carboxylic acids (e.g., acetaldehyde into acetate, hexanal into hexanoate), or reduced to alcohols by alcohol dehydrogenases (ADHs) . Both ALDHs and ALHs are very abundant in human liver [22–24]. ALDHs catalyze the oxidation of a wide range of aromatic and aliphatic aldehydes, however, acetaldehyde is believed to be their most important substrate. Despite the fact that ADHs can also convert aldehydes into alcohols , their primary function in human liver seems to be the breakdown of alcohols (mainly ethanol) naturally contained in food . Moreover, the expression of ALDHs and their enzymatic activity were also evidenced to be elevated in liver cancer cells . Thus, oxidation by ALDHs appears to be the main reason of the uptake of the aldehydes observed within this study.
The activity of another abundant class of human liver enzymes, namely carboxylesterases (CESs) , can explain the observed uptake of two esters n-butyl acetate and n-propyl propionate. For example, CESs could catalyze the hydrolysis of n-butyl acetate into acetic acid and 1-butanol, which could be converted into n-butanal by ADHs and subsequently into butanoic acid by ALDHs. The aforementioned hypothesis is supported by the fact that lung cells (both cancer and normal) exhibiting also elevated CESs levels  were found to consume n-butyl acetate during in vitro studies [12, 15].
The fivefold decrease of the isoprene levels in the HepG2 culture headspace is consistent with the previous experiments demonstrating the cytochrome P450 oxidation of this hydrocarbon to mono- and di-epoxides by human liver microsomes [28–31]. Thus, in human liver isoprene is metabolized mainly to 3,4-epoxy-3-methyl-1-butene and 3,4-epoxy-2-methyl-1-butene, which next are hydrolysed by epoxide hydrolase to vicinal diols (2-methyl-3-buten-1,2-diol and 3-methyl-3-buten-1,2-diol). Isoprene metabolism in the liver was also suggested by Miekisch et al.  on the basis of relatively low hepatic venous blood concentrations of this hydrocarbon in pigs. Isoprene is the major hydrocarbon produced in human organism exhibiting high abundances in breath (mean 100 ppb) and blood [32, 33]. The most widespread hypothesis suggests that isoprene in humans is a by-product of cholesterol biosynthesis [4, 33]. According to it isoprene is produced non-enzymatically by acid-catalyzed formation from dimethylallyl pyrophosphate (DMAPP). However, this reaction is rather slow at physiological pH and unlikely to completely explain the high isoprene levels in human organism [34, 35]. Indeed, there is growing evidence provided by a number of recent studies suggesting that other metabolic sources may contribute to isoprene formation in the humans [32, 33, 36, 37]. In this context it is interesting to note that the isoprene concentration in human breath increases approximately by a factor of 5 during exertion of effort on a stationary bicycle [37–42]. Isoprene might therefore not only be produced in the liver, but also in the muscles.
The studies on uptakes and releases of volatile organic compounds by human cell lines are relatively sparse. Consequently, it is difficult to relate findings obtained within this study to available literature data. Up to now only lung cells (both cancer and normal) received more widespread attention. Similar as in the case of HepG2 cells an uptake of aldehydes has been reported in cultures of human lung cancer cells [12, 13, 15]. This is not surprising as ALDHs are also highly expressed in lung cancer cells . Conversely, Rutter et al.  demonstrated that the release of acetaldehyde by lung cancer cells was three times higher than by normal ones. However, this finding could be the result of different media composition (e.g. presence or absence of ethanol) and unequal increase of ADHs and ALDHs activity in cancer cells . Nevertheless, a similar consumption has also been observed in cultures of normal lung cells . Both cancer and normal lung cells were also shown to metabolise some esters (e.g. n-butyl acetate) during in vitro studies [12, 15], which can be associated with the high expression of CESs in lung tissue .
Release of VOCs by HepG2 cells
Twelve compounds were found to be released by HepG2 cells (see Table 3). The predominantly represented chemical classes within this group were ketones and volatile sulphur compounds (VSCs), both with five species (2-pentanone, 3-heptanone2-heptanone3-octanone, 2-nonanone, dimethyl sulfide, ethyl methyl sulfide, 3-methyl thiophene, 2-methyl-1-(methylthio)- propane, and 2-methyl-5-(methylthio) furan). There was also one hydrocarbon (2-heptene) and one ester (n-propyl acetate). Two compounds (2-heptene and 2-methyl-1-(methylthio)- propane) were not quantified due to the unavailability of pure substances from commercial vendors and their levels were assessed only on the basis of peak areas. The highest concentrations were observed for dimethyl sulfide (DMS; mean of 41 ppb in cell cultures vs. 8.6 ppb in media) and 2-pentanone (3.8 vs 0.45 ppb). The majority of the remaining species exhibited mean concentration values below 1 ppb after 24 hours of incubation.
A potential pathway leading to ketones production by HepG2 cells involves alcohol dehydrogenases (ADHs). ADHs are very abundant in liver and play a major role in hepatic ethanol metabolism [22, 23, 25, 46]. They are also capable of metabolizing longer-chain and cyclic alcohols, however, primary alcohols seem to be their preferred substrates [22, 23]. Although secondary alcohols were shown to be rather poor substrates for ADHs , catalysis of ketones production from secondary alcohols has been evidenced in the literature (e.g., acetone from 2-propanol, 2-octanone from 2-octanol) [23, 25, 47]. Moreover, the total alcohol dehydrogenases activity is significantly higher in liver cancer tissues than in healthy ones, significantly exceeding the activity of ALDHs [45, 48]. Thus, all observed ketones can originate from the respective secondary alcohols. The source of the secondary alcohols remains unclear. Perhaps the applied medium contained small amounts of long-chain secondary alcohols. An alternative pathway leading to the formation of heavier ketones in humans is β-oxidation of branched-chain fatty acids. For example, 3-heptanone was found to be a product of valproic acid metabolism  and 4-heptanone was shown to originate from 2-ethylhexanoic acid . The potential substrates for this metabolic pathway could in turn be metabolites of the respective branched-chain primary alcohols (e.g. 2-ethylhexanoic acid from 2-ethylhexanol). However, it is not clear if these substrates were present in the applied medium.
The second most dominant chemical class amongst the released species were volatile sulphur compounds (VSCs) with DMS as the most abundant analyte. The production of VSCs in humans is ascribed to the metabolization of the sulfur-containing amino acids methionine and cysteine in the transamination pathway . In liver thiol S-methyltransferase forms methyl thioethers via the methylation of thiols [50–52]. For instance, DMS is formed via the methylation of methyl mercaptane . Although production of methanethiol by L-methionine γ-lyase in humans is well documented, little is known about the formation of other thiols.
The origin of the two remaining species n-propyl acetate and 2-heptene remains unclear.
Whereas, human lung cells were reported to release some ketones (e.g. 2-pentanone, 2-hexanone, 2-octanone) [12, 14], none sulphur species were observed to be liberated by these cells. This difference could be ascribed to the expression of liver-specific enzymes. Amongst hydrocarbons (HCs), only 2-heptene was found to be produced by HepG2. This finding clearly distinguishes HepG2 cells from lung cancer cells liberating numerous unsaturated and branched hydrocarbons [12, 15]. Nevertheless, this chemical class is of particular interest as some HCs have been proposed as non-invasive markers of numerous diseases in the human organism [6–8] and their origin is still not clear. Interestingly, n-propyl acetate found to be emitted by HepG2 is also released by normal lung cells but not by cancer ones .
The present study aimed at the identification and quantification of volatile organic compounds emitted or metabolized by HepG2 hepatocellular carcinoma cells. For this purpose gas chromatography with mass spectrometric detection coupled with head-space needle trap extraction (HS-NTD) as pre-concentration technique was applied. Nine species were found to be consumed and further 12 released by HepG2 cells. The emission and uptake of the aforementioned species may be explained by the activity of enzymes that are particularly abundant in human liver and additionally highly expressed in cancer cells. Thus, aldehydes were probably oxidized by aldehyde dehydrogenases to carboxylic acids, ketones were presumably the products of branched, or secondary alcohols metabolism and thioethers release could be an expression of thiol S-methyltransferase activity.
Several limitation of the study can be indicated. Firstly, the study involved transformed hepatocytes, which may exhibit an altered metabolism as compared to the normal ones [26, 45]. Next, no additional liver-resident cells were included in the present study (e.g. representing other tissues of this complex organ). Thus, their contribution to the production and metabolism of VOCs in the liver remains to be established. Moreover, in vivo metabolic pathways may be regulated by numerous factors (e.g. hormones, ATP levels, oxygen concentration), which may have been lacking in our in vitro experiments. The initial background levels of VOCs were not strictly equal during cultivations. This results from the fact, that before each experiment fresh medium was prepared and purged, frequently from components originating from different production lots. These initial VOC levels could also be affected by small fluctuations of purging conditions (e.g. flow rate). Consequently, the production and consumption rates of VOCs under study did not depend exclusively on the number of cells and their metabolism.
In summary, the analysis of volatile organic compounds has the potential to identify and monitor enzyme activities. This feature may be helpful for the detection and analysis of cancers, which may carry mutations in metabolic enzymes [26, 45, 53].
Chemicals and calibration mixtures
Gaseous multi-compound calibration mixtures were prepared from pure liquid substances. The majority of them were purchased from Sigma-Aldrich (Austria); 2-methyl 2-propenal (95%), 2-methyl propanal (99.5%), ethyl methyl sulfide (95.5%), 3-methyl butanal (97%), 2-pentanone (99%), n-propyl acetate (98%), 3-methyl thiophene (98%), n-hexanal (98%), isoprene (99%) and 2-heptanone (98%). Moreover, dimethyl sulfide (99%), n-butyl acetate (99.7%), benzaldehyde (99%) and 2-methyl butanal (99%) were obtained from Fluka (Switzerland), whereas n-propyl propionate (98%) was provided by SAFC (USA). 3-Octanone (99%) was purchased from Acros Organic (Belgium), 3-heptanone (98%) from Alfa Aesar (USA), 2-methyl-5-(methylthio) furan (99%) from Chemos (Germany) and 2-nonanone (98%) from Merck Schuchardt (Germany).
Gaseous calibration mixtures were produced by means of a GasLab calibration mixtures generator (Breitfuss Messtechnik, Germany). The GasLab unit consists of an integrated zero air generator, a 2-stage dynamic injection module for evaporating a liquid and diluting it with zero air, and a humidification module enabling the preparation of gas mixtures at well-defined humidity levels (up to 100% relative humidity (RH) at 37°C). When using pure liquid substances GasLab is able to produce a flow of up to 10 L/min of complex trace gas mixtures diluted in dry or humidified zero air containing from 10 ppb to 100 ppm of each solute. However, for the goals of this study, pure substances were additionally diluted (1:2000–1:3000) with distilled water prior to evaporation in order to reduce the resulting concentration levels. Effectively, humid gas mixtures (100% RH at 37°C) with volume fractions ranging from approximately 0.04 to 350 ppb were used during calibration and validation. The calibration mixtures were sampled and analyzed using identical conditions as in the case of head-space measurements of cell cultures and blanks (i.e. volume of 200 ml at a flow rate of 10 ml/min at 37°C).
In addition to the experiments involving cells cultures, blank (control) experiments were performed in parallel. These blank experiments followed the same protocol as mentioned above, however, without the addition of cells into the measurement bottles. An effort was made to always use the same flushed medium in blanks and corresponding cell cultures. The reproducibility of such a protocol was checked by a comparison of head-space levels of compounds under study (consumed ones) in five cultivation bottles containing the same medium after 24 hours of simulated cultivation. The calculated RSDs were smaller than 10%.
NTD extraction procedure and chromatographic analysis
Volatile compounds were pre-concentrated manually using three-bed side-hole 23-gauge stainless steel needle trap devices (NTD) (PAS Technology, Germany) [54–56]. All needles were Silcosteel-treated and their sorbent beds consisted of 1 cm of Tenax TA (80/100 mesh), 1 cm of Carbopack X (60/80 mesh) and 1 cm of Carboxen 1000 (60/80 mesh). Prior to the first use all NTDs were pre-conditioned at 290°C by flushing them with high-purity nitrogen (6.0 – 99.9999%) for 4 h. Their re-conditioning was performed directly before sampling at the same temperature, however, with shorter flushing times of 10 minutes. Since NTDs were found to exhibit relatively huge differences with respect to the extraction efficiency (deviations of up to 70%, even when originating from the same production lot) the NTDs used during experiments were pre-selected according to the requirement that their inter-needle variability should be below 10%.
NTD trapping of headspace constituents was accomplished dynamically by inserting the NTD through a rubber septum into the headspace of the bottle and drawing 200 mL of sample at a steady flow rate of 10 mL/min at 37°C. This was done with the help of a membrane pump (Vacuubrand, Germany) and a mass flow controller (RED-Y, Burde Co. GmbH, Austria). Consequently, no transfer line had to be installed between the headspace sample and the needle trap. To maintain a constant pressure during sampling high purity zero air was continuously introduced into the bottle at a flow equal to the sampling flow. Following extraction the NTD was manually introduced into the inlet of the gas chromatograph where the compounds of interest were thermally desorbed at 290°C in a splitless mode (1 min).
Chromatographic analyses were performed using an Agilent 7890A/5975C GC-MS system (Agilent, USA). During NTD desorption, the split/splitless inlet operated in the splitless mode (1 min), followed by a split mode at ratio 1:20. The volatiles of interest were separated using a PoraBond Q column (25 m × 0.32 mm, film thickness 5 μm, Varian, USA) working in a constant flow mode (helium at 1.5 mL/min). The column temperature program was as follows: 40°C for 5 min, increase to 260°C at a rate of 7°C/min, followed by a constant temperature phase at 260°C for 6 min. The mass spectrometer worked in a SCAN mode with an associated m/z range set from 20 to 200. The quadrupole, ion source, and transfer line temperatures were kept at 150°C, 230°C, and 280°C, respectively.
The identification of compounds was performed in two steps. At first, the peak spectrum was checked against the NIST mass spectral library. Next, the NIST identification was confirmed by comparing the respective retention times with retention times obtained on the basis of standard mixtures prepared from pure compounds. Peak integration was based on extracted ion chromatograms. The retention times of the investigated compounds for the applied chromatographic parameters as well as the ions used for the integration are presented in Table 1.
P.M, J.K., and K.U. gratefully acknowledge support from the Austrian Science Fund (FWF) under Grant No. P24736-B23. We appreciate support from the Austrian Agency for International Cooperation (OEAD, project SPA_04/158 – FEM_PERS) and funding by the Scientific and Technological Cooperation (Wissenschaftlich-Technische Zusammenarbeit - WTZ) between Austria and Poland (project no PL 02/2012). We greatly appreciate the generous support of the government of Vorarlberg, Austria.
- Amann A, Poupart G, Telser S, Ledochowski M, Schmid A, Mechtcheriakov S: Applications of breath gas analysis in medicine. Int J Mass Spectrometry. 2004, 239: 227-233. 10.1016/j.ijms.2004.08.010.View ArticleGoogle Scholar
- Amann A, Smith D: Breath analysis for clinical diagnosis and therapeutic monitoring. 2005, New Jersey: World ScientificGoogle Scholar
- Erhart S, Amann A, Haberlandt E, Edlinger G, Schmid A, Filipiak W, Schwarz K, Mochalski P, Rostasy K, Karall D: 3-Heptanone as a potential new marker for valproic acid therapy. J Breath Res. 2009, 3 (1): 016004-10.1088/1752-7155/3/1/016004.View ArticlePubMedGoogle Scholar
- Miekisch W, Schubert JK, Noeldge-Schomburg GF: Diagnostic potential of breath analysis–focus on volatile organic compounds. Clin Chim Acta. 2004, 347 (1–2): 25-39.View ArticlePubMedGoogle Scholar
- Filipiak W, Sponring A, Filipiak A, Baur M, Ager C, Wiesenhofer H, Margesin R, Nagl M, Troppmair J, Amann A: Volatile Organic Compounds (VOCs) Released by athogenic Microorganisms in Vitro: Potential Breath Biomarkers for Early-Stage Diagnosis of Disease. Volatile Biomarkers: Non-Invasive Diagnosis in Physiology and Medicine. Edited by: Amann A. 2013, SD: ElsevierGoogle Scholar
- Bajtarevic A, Ager C, Pienz M, Klieber M, Schwarz K, Ligor M, Ligor T, Filipiak W, Denz H, Fiegl M: Noninvasive detection of lung cancer by analysis of exhaled breath. BMC Cancer. 2009, 9: 348-10.1186/1471-2407-9-348.PubMed CentralView ArticlePubMedGoogle Scholar
- Phillips M, Altorki N, Austin JH, Cameron RB, Cataneo RN, Kloss R, Maxfield RA, Munawar MI, Pass HI, Rashid A: Detection of lung cancer using weighted digital analysis of breath biomarkers. Clin Chim Acta. 2008, 393 (2): 76-84. 10.1016/j.cca.2008.02.021.PubMed CentralView ArticlePubMedGoogle Scholar
- Poli D, Carbognani P, Corradi M, Goldoni M, Acampa O, Balbi B, Bianchi L, Rusca M, Mutti A: Exhaled volatile organic compounds in patients with non-small cell lung cancer: cross sectional and nested short-term follow-up study. Respir Res. 2005, 6: 71-10.1186/1465-9921-6-71.PubMed CentralView ArticlePubMedGoogle Scholar
- Wehinger A, Schmid A, Mechtcheriakov S, Ledochowski M, Grabmer C, Gastl GA, Amann A: Lung cancer detection by proton transfer reaction mass-spectrometric analysis of human breath gas. Int J Mass Spectrom. 2007, 265 (1): 49-59. 10.1016/j.ijms.2007.05.012.View ArticleGoogle Scholar
- Kanoh S, Kobayashi H, Motoyoshi K: Exhaled ethane: an in vivo biomarker of lipid peroxidation in interstitial lung diseases. Chest. 2005, 128 (4): 2387-2392. 10.1378/chest.128.4.2387.View ArticlePubMedGoogle Scholar
- Scholpp J, Schubert JK, Miekisch W, Geiger K: Breath markers and soluble lipid peroxidation markers in critically ill patients. Clin Chem Lab Med. 2002, 40 (6): 587-594.View ArticlePubMedGoogle Scholar
- Filipiak W, Sponring A, Filipiak A, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J: TD-GC-MS analysis of volatile metabolites of human lung cancer and normal cells in vitro. Cancer Epidemiol. Biomarkers Prev. 2010, 19 (1): 182-195. 10.1158/1055-9965.EPI-09-0162.View ArticlePubMedGoogle Scholar
- Filipiak W, Sponring A, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J: Release of volatile organic compounds (VOCs) from the lung cancer cell line CALU-1 in vitro. Cancer Cell Int. 2008, 8: 17-10.1186/1475-2867-8-17.PubMed CentralView ArticlePubMedGoogle Scholar
- Hanai Y, Shimono K, Oka H, Baba Y, Yamazaki K, Beauchamp GK: Analysis of volatile organic compounds released from human lung cancer cells and from the urine of tumor-bearing mice. Cancer Cell Int. 2012, 12 (1): 7-10.1186/1475-2867-12-7.PubMed CentralView ArticlePubMedGoogle Scholar
- Sponring A, Filipiak W, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J: Analysis of volatile organic compounds (VOCs) in the headspace of NCI-H1666 lung cancer cells. Cancer Biomark. 2010, 7 (3): 153-161.PubMedGoogle Scholar
- Sponring A, Filipiak W, Mikoviny T, Ager C, Schubert J, Miekisch W, Amann A, Troppmair J: Release of volatile organic compounds from the lung cancer cell line NCI-H2087 in vitro. Anticancer Res. 2009, 29 (1): 419-426.PubMedGoogle Scholar
- Buszewski B, Ulanowska A, Ligor T, Jackowski M, Klodzinska E, Szeliga J: Identification of volatile organic compounds secreted from cancer tissues and bacterial cultures. J Chromatogr B Analyt Technol Biomed Life Sci. 2008, 868 (1–2): 88-94.View ArticlePubMedGoogle Scholar
- Filipiak W, Sponring A, Baur MM, Ager C, Filipiak A, Wiesenhofer H, Nagl M, Troppmair J, Amann A: Characterization of volatile metabolites taken up by or released from Streptococcus pneumoniae and Haemophilus influenzae by using GC-MS. Microbiology. 2012, 158 (Pt 12): 3044-3053.View ArticlePubMedGoogle Scholar
- Filipiak W, Sponring A, Baur MM, Filipiak A, Ager C, Wiesenhofer H, Nagl M, Troppmair J, Amann A: Molecular analysis of volatile metabolites released specifically by Staphylococcus aureus and Pseudomonas aeruginosa. BMC Microbiol. 2012, 12: 113-10.1186/1471-2180-12-113.PubMed CentralView ArticlePubMedGoogle Scholar
- Castaneda F, Zimmermann D, Nolte J, Baumbach JI: Role of undecan-2-one on ethanol-induced apoptosis in HepG2 cells. Cell Biol Toxicol. 2007, 23 (6): 477-485. 10.1007/s10565-007-9009-y.View ArticlePubMedGoogle Scholar
- Huber W: Basic calculations about the limit of detection and its optimal determination. Accred Qual Assur. 2003, 8: 213-217.Google Scholar
- Crabb DW, Matsumoto M, Chang D, You M: Overview of the role of alcohol dehydrogenase and aldehyde dehydrogenase and their variants in the genesis of alcohol-related pathology. Proc Nutr Soc. 2004, 63 (1): 49-63. 10.1079/PNS2003327.View ArticlePubMedGoogle Scholar
- Ditlow CC, Holmquist B, Morelock MM, Vallee BL: Physical and enzymatic properties of a class II alcohol dehydrogenase isozyme of human liver: pi-ADH. Biochemistry. 1984, 23 (26): 6363-6368. 10.1021/bi00321a012.View ArticlePubMedGoogle Scholar
- Klyosov AA: Kinetics and specificity of human liver aldehyde dehydrogenases toward aliphatic, aromatic, and fused polycyclic aldehydes. Biochemistry. 1996, 35 (14): 4457-4467. 10.1021/bi9521102.View ArticlePubMedGoogle Scholar
- Wagner FW, Pares X, Holmquist B, Vallee BL: Physical and enzymatic properties of a class III isozyme of human liver alcohol dehydrogenase: chi-ADH. Biochemistry. 1984, 23 (10): 2193-2199. 10.1021/bi00305a014.View ArticlePubMedGoogle Scholar
- Ma S, Chan KW, Lee TK, Tang KH, Wo JY, Zheng BJ, Guan XY: Aldehyde dehydrogenase discriminates the CD133 liver cancer stem cell populations. Molecular cancer research : MCR. 2008, 6 (7): 1146-1153. 10.1158/1541-7786.MCR-08-0035.View ArticlePubMedGoogle Scholar
- Imai T: Human carboxylesterase isozymes: catalytic properties and rational drug design. Drug Metab Pharmacokinet. 2006, 21 (3): 173-185. 10.2133/dmpk.21.173.View ArticlePubMedGoogle Scholar
- Del Monte M, Citti L, Gervasi PG: Isoprene metabolism by liver microsomal mono-oxygenases. Xenobiotica. 1985, 15 (7): 591-597. 10.3109/00498258509045888.View ArticlePubMedGoogle Scholar
- Watson WP, Cottrell L, Zhang D, Golding BT: Metabolism and molecular toxicology of isoprene. Chem Biol Interact. 2001, 135–136: 223-238.View ArticlePubMedGoogle Scholar
- Bogaards JJ, Freidig AP, van Bladeren PJ: Prediction of isoprene diepoxide levels in vivo in mouse, rat and man using enzyme kinetic data in vitro and physiologically-based pharmacokinetic modelling. Chem Biol Interact. 2001, 138 (3): 247-265. 10.1016/S0009-2797(01)00276-9.View ArticlePubMedGoogle Scholar
- Small RD, Golding BT, Watson WP: Species differences in the stereochemistry of the metabolism of isoprene in vitro. Xenobiotica. 1997, 27 (11): 1155-1164. 10.1080/004982597239912.View ArticlePubMedGoogle Scholar
- Miekisch W, Schubert JK, Vagts DA, Geiger K: Analysis of volatile disease markers in blood. Clin Chem. 2001, 47 (6): 1053-1060.PubMedGoogle Scholar
- Kushch I, Arendacka B, Stolc S, Mochalski P, Filipiak W, Schwarz K, Schwentner L, Schmid A, Dzien A, Lechleitner M: Breath isoprene–aspects of normal physiology related to age, gender and cholesterol profile as determined in a proton transfer reaction mass spectrometry study. Clin Chem Lab Med. 2008, 46 (7): 1011-1018.View ArticlePubMedGoogle Scholar
- Sharkey TD: Isoprene synthesis by plants and animals. Endeavour. 1996, 20 (2): 74-78. 10.1016/0160-9327(96)10014-4.View ArticlePubMedGoogle Scholar
- Silver GM, Fall R: Enzymatic synthesis of isoprene from dimethylallyl diphosphate in aspen leaf extracts. Plant Physiol. 1991, 97 (4): 1588-1591. 10.1104/pp.97.4.1588.PubMed CentralView ArticlePubMedGoogle Scholar
- McGrath LT, Patrick R, Silke B: Breath isoprene in patients with heart failure. Eur J Heart Fail. 2001, 3 (4): 423-427. 10.1016/S1388-9842(01)00128-3.View ArticlePubMedGoogle Scholar
- King J, Mochalski P, Unterkofler K, Teschl G, Klieber M, Stein M, Amann A, Baumann M: Breath isoprene: muscle dystrophy patients support the concept of a pool of isoprene in the periphery of the human body. Biochem Biophys Res Commun. 2012, 423 (3): 526-530. 10.1016/j.bbrc.2012.05.159.View ArticlePubMedGoogle Scholar
- Koc H, King J, Teschl G, Unterkofler K, Teschl S, Mochalski P, Hinterhuber H, Amann A: The role of mathematical modeling in VOC analysis using isoprene as a prototypic example. J Breath Res. 2011, 5 (3): 037102-10.1088/1752-7155/5/3/037102.View ArticlePubMedGoogle Scholar
- King J, Mochalski P, Kupferthaler A, Unterkofler K, Koc H, Filipiak W, Teschl S, Hinterhuber H, Amann A: Dynamic profiles of volatile organic compounds in exhaled breath as determined by a coupled PTR-MS/GC-MS study. Physiol Meas. 2010, 31 (9): 1169-1184. 10.1088/0967-3334/31/9/008.View ArticlePubMedGoogle Scholar
- King J, Kupferthaler A, Unterkofler K, Koc H, Teschl S, Teschl G, Miekisch W, Schubert J, Hinterhuber H, Amann A: Isoprene and acetone concentration profiles during exercise on an ergometer. J Breath Res. 2009, 3 (2): 027006-10.1088/1752-7155/3/2/027006.View ArticlePubMedGoogle Scholar
- King J, Koc H, Unterkofler K, Mochalski P, Kupferthaler A, Teschl G, Teschl S, Hinterhuber H, Amann A: Physiological modeling of isoprene dynamics in exhaled breath. J Theor Biol. 2010, 267 (4): 626-637. 10.1016/j.jtbi.2010.09.028.View ArticlePubMedGoogle Scholar
- King J, Kupferthaler A, Frauscher B, Hackner H, Unterkofler K, Teschl G, Hinterhuber H, Amann A, Hogl B: Measurement of endogenous acetone and isoprene in exhaled breath during sleep. Physiol Meas. 2012, 33 (3): 413-428. 10.1088/0967-3334/33/3/413.View ArticlePubMedGoogle Scholar
- Moreb JS, Zucali JR, Ostmark B, Benson NA: Heterogeneity of aldehyde dehydrogenase expression in lung cancer cell lines is revealed by Aldefluor flow cytometry-based assay. Cytometry B Clin Cytom. 2007, 72 (4): 281-289.View ArticlePubMedGoogle Scholar
- Rutter AV, Chippendale TW, Yang Y, Spanel P, Smith D, Sule-Suso J: Quantification by SIFT-MS of acetaldehyde released by lung cells in a 3D model. Analyst. 2013, 138 (1): 91-95. 10.1039/c2an36185j.View ArticlePubMedGoogle Scholar
- Jelski W, Szmitkowski M: Alcohol dehydrogenase (ADH) and aldehyde dehydrogenase (ALDH) in the cancer diseases. Clin Chim Acta. 2008, 395 (1–2): 1-5.View ArticlePubMedGoogle Scholar
- Burnell JC, Li TK, Bosron WF: Purification and steady-state kinetic characterization of human liver beta 3 beta 3 alcohol dehydrogenase. Biochemistry. 1989, 28 (17): 6810-6815. 10.1021/bi00443a005.View ArticlePubMedGoogle Scholar
- Kedishvili NY, Bosron WF, Stone CL, Hurley TD, Peggs CF, Thomasson HR, Popov KM, Carr LG, Edenberg HJ, Li TK: Expression and kinetic characterization of recombinant human stomach alcohol dehydrogenase. Active-site amino acid sequence explains substrate specificity compared with liver isozymes. J Biol Chem. 1995, 270 (8): 3625-3630. 10.1074/jbc.270.8.3625.View ArticlePubMedGoogle Scholar
- Jelski W, Zalewski B, Szmitkowski M: Alcohol dehydrogenase (ADH) isoenzymes and aldehyde dehydrogenase (ALDH) activity in the sera of patients with liver cancer. J Clin Lab Anal. 2008, 22 (3): 204-209. 10.1002/jcla.20241.View ArticlePubMedGoogle Scholar
- Walker V, Mills GA: Urine 4-heptanone: a beta-oxidation product of 2-ethylhexanoic acid from plasticisers. Clin Chim Acta. 2001, 306 (1–2): 51-61.View ArticlePubMedGoogle Scholar
- Tangerman A: Measurement and biological significance of the volatile sulfur compounds hydrogen sulfide, methanethiol and dimethyl sulfide in various biological matrices. J Chromatogr B Analyt Technol Biomed Life Sci. 2009, 877 (28): 3366-3377. 10.1016/j.jchromb.2009.05.026.View ArticlePubMedGoogle Scholar
- Glauser TA, Kerremans AL, Weinshilboum RM, 2: 1992. Drug Metab Dispos. 1992, 20: 247-255.PubMedGoogle Scholar
- Weisiger RA, Jakoby WB: Thiol S-methyltransferase from rat liver. Arch Biochem Biophys. 1979, 196 (2): 631-637. 10.1016/0003-9861(79)90317-5.View ArticlePubMedGoogle Scholar
- Reitman ZJ, Parsons DW, Yan H: IDH1 and IDH2: not your typical oncogenes. Cancer Cell. 2010, 17 (3): 215-216. 10.1016/j.ccr.2010.02.024.PubMed CentralView ArticlePubMedGoogle Scholar
- Filipiak W, Filipiak A, Ager C, Wiesenhofer H, Amann A: Optimization of sampling parameters for collection and preconcentration of alveolar air by needle traps. J Breath Res. 2012, 6 (2): 027107-10.1088/1752-7155/6/2/027107.View ArticlePubMedGoogle Scholar
- Gong Y, Eom IY, Lou DW, Hein D, Pawliszyn J: Development and application of a needle trap device for time-weighted average diffusive sampling. Anal Chem. 2008, 80 (19): 7275-7282. 10.1021/ac800884f.View ArticlePubMedGoogle Scholar
- Mieth M, Kischkel S, Schubert JK, Hein D, Miekisch W: Multibed needle trap devices for on site sampling and preconcentration of volatile breath biomarkers. Anal Chem. 2009, 81 (14): 5851-5857. 10.1021/ac9009269.View ArticlePubMedGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.